VKTX
The countdown is on
Viking Therapeutics is officially on the earnings calendar for Wednesday, April 22, after the bell. If you’re keeping score at home, Wall Street is looking for a Q1 loss of $1.01 per share — which means the market isn’t exactly expecting a glitter bomb of profits here.
Why this matters
For biotech names like Viking, earnings aren’t just about the spreadsheet. They’re about runway, trial momentum, and whether the market still believes the story. When a company is valued like a high-growth moonshot, every quarterly update becomes a vibe check.
A stock that still has plenty of believers
The article also notes the stock is trading around $35.52, with analysts still hanging onto a “Moderate Buy” view and an average price target north of $94. That’s a pretty wide gap, which is finance-speak for: either the bulls think the market is sleeping on Viking, or the bears think those targets were written in crayon.
The side plot: insiders are buying
There’s also some insider action in the background — Neil William Aubuchon bought 4,475 shares at $33.50 back on March 10. Insider buys don’t guarantee anything, but they do tend to make investors lean in a little harder when the next earnings call is around the corner.
Big picture: this isn’t a make-or-break earnings date so much as a fresh checkpoint. If Viking can show the story still has legs, the stock could keep riding on hope and headlines. If not, the gap between the current price and those lofty targets may look a lot less glamorous.